These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12457077)

  • 1. The economics of Alzheimer disease.
    Leung GM; Yeung RY; Chi I; Chu LW
    Dement Geriatr Cogn Disord; 2003; 15(1):34-43. PubMed ID: 12457077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic research on Alzheimer disease: a review of the literature.
    Ernst RL; Hay JW
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 6():135-45. PubMed ID: 9437458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of mild cognitive impairment.
    Lin PJ; Neumann PJ
    Alzheimers Dement; 2013 Jan; 9(1):58-62. PubMed ID: 23141385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
    Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
    Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic considerations in the treatment and management of Alzheimer's disease.
    Schumock GT
    Am J Health Syst Pharm; 1998 Nov; 55 Suppl 2():S17-21. PubMed ID: 9809107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients.
    Beeri MS; Werner P; Davidson M; Noy S
    Int J Geriatr Psychiatry; 2002 May; 17(5):403-8. PubMed ID: 11994927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
    Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
    J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease.
    Neumann PJ; Hermann RC; Berenbaum PA; Weinstein MC
    Psychiatr Serv; 1997 Nov; 48(11):1440-4. PubMed ID: 9355172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender Differences: A Lifetime Analysis of the Economic Burden of Alzheimer's Disease.
    Yang Z; Levey A
    Womens Health Issues; 2015; 25(5):436-40. PubMed ID: 26363924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An economic perspective on Alzheimer's disease.
    Trabucchi M
    J Geriatr Psychiatry Neurol; 1999; 12(1):29-38. PubMed ID: 10447152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The economic and social burden of Alzheimer disease on families in the Lombardy region of Italy.
    Cavallo MC; Fattore G
    Alzheimer Dis Assoc Disord; 1997 Dec; 11(4):184-90. PubMed ID: 9437435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom.
    Getsios D; Blume S; Ishak KJ; Maclaine G; Hernández L
    Alzheimers Dement; 2012 Jan; 8(1):22-30. PubMed ID: 21420366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic impact of moderate stage Alzheimer's disease in Italy: evidence from the UP-TECH randomized trial.
    Chiatti C; Furneri G; Rimland JM; Demma F; Bonfranceschi F; Cassetta L; Masera F; Cherubini A; Corsonello A; Lattanzio F;
    Int Psychogeriatr; 2015 Sep; 27(9):1563-72. PubMed ID: 25874654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of health economic analyses in atopic dermatitis: how diverse is the literature?
    Gutknecht M; Reinert R; Augustin M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):127-145. PubMed ID: 30590976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of Alzheimer's disease in a developing country setting.
    Zencir M; Kuzu N; Beşer NG; Ergin A; Catak B; Sahiner T
    Int J Geriatr Psychiatry; 2005 Jul; 20(7):616-22. PubMed ID: 16021668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic outcomes and levers: impacts for individuals and society.
    Knapp M
    Int Psychogeriatr; 2007 Jun; 19(3):483-95. PubMed ID: 17391570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health economic studies: an introduction to cost-benefit, cost-effectiveness, and cost-utility analyses.
    Angevine PD; Berven S
    Spine (Phila Pa 1976); 2014 Oct; 39(22 Suppl 1):S9-15. PubMed ID: 25299265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada.
    Gagnon M; Rive B; Hux M; Guilhaume C
    Can J Psychiatry; 2007 Aug; 52(8):519-26. PubMed ID: 17955915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.